Granules India Receives Usfda Approval For Generic Heartburn Medication

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Granules India receives USFDA approval for generic heartburn medication

ri-calendar-2-lineOct 19, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Granules India Ltd has gained approval from the US Food & Drug Administration (USFDA) for its generic Esomeprazole Magnesium delayed-release capsules. These capsules are designed for the short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease.

 

The approval covers strengths of 20 mg and 40 mg. Granules India affirmed that its product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nexium Delayed-Release Capsules, 20 mg and 40 mg, marketed by AstraZeneca Pharmaceuticals LP.

 

Esomeprazole Magnesium capsules are used for the short-term treatment of heartburn and related symptoms of GERD. They also serve in the risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers in adults and for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

 

According to IQVIA/IMS Health July 2023 data, the current annual market for Esomeprazole Magnesium delayed-release capsules in the US is approximately USD 168 million. This regulatory approval marks a significant advancement for Granules India in expanding its portfolio of generic medications.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions